Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. - Wikidata - awgldk - TriplyDB

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q36915163

about

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives Cancer drug resistance: redox resetting renders a way Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Systemic therapies for pancreatic cancer--the role of pharmacogenetics Germline pharmacogenomics in oncology: decoding the patient for targeting therapy Irinotecan pharmacogenomics Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study UGT genotyping in belinostat dosing Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients Pharmacogene regulatory elements: from discovery to applications Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting Uncovering drug-responsive regulatory elements.Cancer stem cells and chemoresistance: The smartest survives the raid Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.An overview of the recent progress in irinotecan pharmacogenetics.Targeted therapy in GIST: in silico modeling for prediction of resistance.Improving oncology outcomes through targeted therapeutics will require electronic delivery systems.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Application of genotype-guided cancer therapy in solid tumors.The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Personalizing chemotherapy dosing using pharmacological methods.Nuclear receptors and drug metabolism for the personalization of cancer therapy.North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.

P2860

Q26741009-FB795202-C126-46D7-B207-3546330996D5 Q26750753-B9201C3F-C18D-4A50-9523-4E114E5E2592 Q26775949-26F17ADB-0958-4A34-B1F9-0BF0AA1AF542 Q26859144-DF62950B-36D6-4B7F-8B03-14ABE4DC3C5B Q27021716-0879A85B-447D-4675-A033-3E9709A941E8 Q27022557-2DD99C44-FA74-4B35-A0F2-0A9159B86BEF Q28287024-16960B82-6718-4150-89C7-547D4C80CC86 Q28543429-A1F51270-048C-472E-9402-88807D0987B1 Q33429235-C512B84A-7A77-4AF9-BFF4-83AEB70CBA30 Q33604248-705C1896-EAF9-4A51-81A3-D6297C960B00 Q33927990-C500E242-E2C4-4C8F-B67B-639750951095 Q34026161-5ABA1D4E-B9F9-48DA-83F5-CDF819427360 Q35008045-F6A7926F-AD9A-44BC-BE64-8976611900AC Q35050772-E0165353-3849-4EDF-A0D4-DF2550A26F8D Q35108413-D142DC39-0744-475C-86B6-58C6B0DE28F8 Q35603648-1C62E4FF-E360-4225-81FC-96D2469F8315 Q36424755-09A3534F-DD84-4F05-A98A-92C52195EE05 Q36427498-404FF10E-054A-4E80-8EBE-743F7BB8992E Q36473365-DE560A16-14AF-4B36-B35F-53733032C699 Q36730432-24217016-ED06-42AB-A122-11AA812D349A Q37000818-DEEEB540-6573-4832-B87C-2ACDA645E654 Q37339628-598F2C3B-F5D7-49F3-A44A-F9F7978995FD Q37383249-2878122A-EAC6-4AFB-98B0-D45E731A398E Q37682812-C2742D4E-6732-47AB-B595-AE9A328C30F1 Q37685527-48340745-DF21-4F5B-BB3B-9B47B438A22D Q37710511-70FE3C94-762B-4EAE-987C-43C71426551C Q37848666-EC7D1479-CC68-41A5-A64C-C3886D5A7110 Q37875079-59AD5489-01A6-4695-9DB0-9D3DC60CDA35 Q37876401-E1435F31-28C8-4CA4-B87F-62DB3BA0B247 Q38005612-5FAD88D9-B28A-4D85-99C2-865DCFB3F107 Q38059508-E60B845A-7B9A-4E10-8135-EF7A591F9D0A Q38107101-B1F5FED9-CB15-4DE6-8184-1A5CEEE20C73 Q38166233-8DD0FE83-5CE3-4EFC-AC46-A7537E609836 Q38170457-09F4ECE6-5B41-42C6-A5AB-DD2E77E47D70 Q38202816-4E4953A1-FF50-4321-8844-514301087919 Q38393997-0D91910E-F0BD-46E0-8287-52C4964800BE Q38571728-98A7EBED-21C2-4387-8149-15C8E63FF1BD Q38704025-4F90833A-43D4-40B5-BD55-C650C5247987 Q38792393-A398576C-F25C-4054-9D26-3044E53E824E Q39200965-30564704-7FBC-4F62-9C42-4E5FB3F00385

P2860

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q36915163

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Genotype-driven phase I study ...... metastatic colorectal cancer.

@en

type

label

Genotype-driven phase I study ...... metastatic colorectal cancer.

@en

prefLabel

Genotype-driven phase I study ...... metastatic colorectal cancer.

@en

P1433

Q36915163-E2795620-BE7B-4CEB-AE2D-AFE6741E25F3

P1476

Q36915163-B6B9831C-EE97-4132-A743-E26760E8B03A

P2093

Q36915163-01BE2D3C-28AF-4CA2-A112-AD346910888F

Q36915163-27295620-5823-4CB4-A8C8-0CEC01B50399

Q36915163-2A52DA4B-92F4-44DF-9D3A-12981B8805AD

Q36915163-3E2363DE-F591-4C31-8209-577C9422C17D

Q36915163-52DDD04F-2595-4828-BCBE-19BF1B2D019C

Q36915163-6C70F0BE-5745-47DC-BBF5-6BCB9ED13E25

Q36915163-BEF0CFCC-4636-422B-8D59-B08B349357EA

Q36915163-E1A0407D-14C8-4D78-AE46-75235E53CC34

P2860

Q36915163-0E70F68C-49E2-4486-AD1B-AC92BF2C6BA1

Q36915163-0FDA75D9-FD9A-4687-96FD-1F0356B77C63

Q36915163-3753D696-02CF-4308-BA62-2AA258FCD942

Q36915163-4235AB2D-5A5F-4C88-8FC8-F4894B8CDEFA

Q36915163-43BF3EDD-844B-429B-8FFE-97F7C020E05B

Q36915163-56AD0BD3-EB2B-4B90-B3B4-36161DC5EE1A

Q36915163-57A37F6D-12CE-4D68-A044-A7FF851FE0C1

Q36915163-595BA8DA-E9F6-4A19-A757-2D3467948DD1

Q36915163-69DF63FA-7D2B-4CFF-932A-C141661C9E5D

Q36915163-8903911A-4EEE-460F-B249-AE468F738C99

P304

Q36915163-F5890799-DF47-4ED9-A0A5-95A795C5722F

P31

Q36915163-8888AA55-BE4D-4EDD-BBDB-83DC62A81C0F

P356

Q36915163-5377EF82-3FCC-4506-9F15-7A7144B6B932

P407

Q36915163-010D5B2E-4F68-4D93-9341-1951B6C5B6E3

P433

Q36915163-BC4BDEC6-BBA8-4EA1-AE26-F465C9009084

P478

Q36915163-901D2849-2B01-41CB-B407-183813F4CE9A

P50

Q36915163-01C6477F-16B9-4C64-A195-11ADD8FD31A0

Q36915163-2B160F2C-A6EA-48EC-9917-6915B20F154C

Q36915163-349A0B75-8400-4259-A007-7DE2B3EEC3DA

Q36915163-93868FFD-C154-4CB7-878B-DC5F8DE990E5

Q36915163-F4777F92-4110-4AE4-955E-5DC5F66B5582

Q36915163-F70430DC-4D73-483D-A32B-7D815B95F597

P577

Q36915163-D48E15C3-EE04-4379-A899-6A04AF6597F0

P698

Q36915163-3E0AB9DF-DDE8-4BD9-A1EB-36AF6F2C1AE1

P921

Q36915163-9F71657A-CE5D-47A0-ABC0-2B2D42ECFD88

P932

Q36915163-291CEC06-C06F-4BBD-A705-1DC1A547DBA9

P356

JCO.2009.23.6125

P1433

Journal of Clinical Oncology

P1476

Genotype-driven phase I study ...... metastatic colorectal cancer.

@en

P2093

Enrico Mini

http://www.w3.org/2001/XMLSchema#string

Erika Cecchin

http://www.w3.org/2001/XMLSchema#string

Federico Innocenti

http://www.w3.org/2001/XMLSchema#string

Giampiero Gasparini

http://www.w3.org/2001/XMLSchema#string

Giuseppe Azzarello

http://www.w3.org/2001/XMLSchema#string

Mario D'Andrea

http://www.w3.org/2001/XMLSchema#string

Sergio Pessa

http://www.w3.org/2001/XMLSchema#string

Stefania Nobili

http://www.w3.org/2001/XMLSchema#string

P2860

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome.

P304

866-871

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.23.6125

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Angela Buonadonna

Elena De Mattia

P577

2009-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20038727

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4872310

http://www.w3.org/2001/XMLSchema#string